Abstract Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention as a prognostic factor in breast cancer. We aimed to validate the influence of Ep-CAM RNA expression in untreated node-negative breast cancer. Ep-CAM RNA expression was evaluated utilizing microarraybased gene-expression profiling in 194 consecutive nodenegative breast cancer patients with long-term follow-up not treated in the adjuvant setting. The prognostic significance of Ep-CAM RNA expression for disease-free survival (DFS), metastasis-free survival (MFS), and breast cancer-specific overall survival (OS) was evaluated in univariate and multivariate analysis adjusted for age, grading, pTstage, ER as well as PR receptor and HER-2 status. Additionally, Ep-CAM RNA expression was compared with immunohistochemistry (IHC) for Ep-CAM in 194 patients. The prognostic impact of Ep-CAM gene expression was validated in further 588 nodenegative breast cancer patients. Levels of Ep-CAM RNA expression showed a significant correlation with IHC (P = 0.001) and predicted in univariate analysis DFS (P = 0.001, HR = 2.4), MFS (P = 0.003, HR = 2.5), and OS (P = 0.002, HR = 3.1) accurately. The prognostic influence of Ep-CAM RNA was significant also in multivariate analysis for DFS (P = 0.017, HR = 2.0), MFS (P = 0.049, HR = 1.9), and OS (P = 0.042, HR = 2.3), respectively. The association with MFS was confirmed in an independent validation cohort in univariate (P = 0.006, HR = 1.9) and multivariate (P = 0.035, HR = 1.7) analysis. Ep-CAM RNA correlated with the proliferation metagene (P \ 0.001, R=0.425) Nevertheless, in multivariate analysis, Ep-CAM was associated with MFS independent from the proliferation metagene (P = 0.030, HR = 1.8). In conclusion, Ep-CAM RNA expression is associated with poor MFS in three cohorts of untreated node-negative breast cancer.
Introduction
The epithelial cell adhesion molecule (Ep-CAM) is a transmembrane glycoprotein expressed on most human epithelial cells, functioning as a homophilic cell-cell adhesion molecule [1] . Ep-CAM is a potential target for antibody based therapies [2] [3] [4] [5] . Recently, we could show that a fully human monoclonal antibody against Ep-CAM has anti-tumor activity in heavily pretreated Ep-CAM positive metastatic breast cancer [6] . Overexpression of Ep-CAM has been reported to correlate with poor diseasefree (DFS) and overall survival (OS) in breast cancer [7] . However, when the prognostic impact of Ep-CAM was later examined in a larger database of 1,705 patients the authors postulated that the adverse prognostic effect of Ep-CAM overexpression was confined to node-positive patients [8] . Since node-positive breast cancer patients usually receive some form of adjuvant systemic therapy, this study does not explain whether the impact of Ep-CAM overexpression is purely prognostic in nature or confounded by predictive effects. The differentiation between prognostic and predictive factors is relevant, since therapeutic targets with prognostic relevance appear more promising [9] . The only possibility to rule out a potentially confounding predictive effect is to examine cohorts of patients without adjuvant systemic treatment. Recently, we have analyzed a cohort of 402 untreated node-negative breast cancer patients for immunohistochemically determined Ep-CAM expression [10] . Indeed, Ep-CAM overexpression carried prognostic significance and was associated with DFS independent from established clinical parameters [10] . Since monoclonal antibodies against Ep-CAM have shown clinical activity in metastatic breast cancer [6] , the matter of definition of the subgroup of patients who profit most from this therapy becomes of increasing relevance. It is plausible that a subgroup of patients in whom Ep-CAM overexpression is associated with worse prognosis is most appropriate for an Ep-CAM antagonizing therapy. Therefore, the aim of the present study was to analyze whether also Ep-CAM RNA expression can be used to identify a subgroup of patients with increased risk. Besides comparing the prognostic relevance of Ep-CAM RNA and protein, we additionally validated the prognostic relevance of Ep-CAM RNA expression in two additional cohorts of node-negative breast cancer [11] [12] [13] . Finally, we studied whether the prognostic influence of Ep-CAM RNA expression is independent from the recently described proliferation metagene [14] .
Patients and methods
The Mainz node-negative cohort consisted of 409 consecutive node-negative breast cancer patients with tumor size pT1 a -pT3 and adequate follow-up information who were treated at the Department of Obstetrics and Gynecology of the Johannes Gutenberg University Mainz between the years 1986 and 2000. Of these 409 patients, paraffin blocks with tumor tissue were available for 402 individuals. In 194 patients, fresh-frozen tissue for microarray-based geneexpression analysis was available [15] . All patients have been treated by surgical tumor resection, but had not received any systemic therapy in the adjuvant setting. Ep-CAM status was collected from a previously published database [10] immunohistochemistry against Ep-CAM was available in 194 patients. Ep-CAM was assessed using an immunoreactive score defined by the product of a proportion score (0, none; 1, \10%; 2, 10-50%; 3, 50-80%; 4, [80% positive cells) and an intensity score (0, no staining; 1, weak; 2, moderate; 3, strong). Besides using the score, Ep-CAM expression was additionally assessed by the Ep-CAM status. Only tumors with strong specific surface membrane staining in more than 10% of the tumor cells were considered as Ep-CAM 3? overexpressors and were thus assigned a positive Ep-CAM status. Patients had been treated either with modified radical mastectomy (44%) or breast conserving surgery followed by irradiation (56%). Patients' characteristics are given in Table 1 . The study was approved by the ethical review board of the medical association of Rhineland-Palatinate. We documented DFS, metastasis-free survival (MFS), and breast cancer-specific OS. The mean follow-up time was 10 years ± 5 years (standard deviation). 58 patients (30%) relapsed, 45 (23%) had distant metastases, and 31 (16%) died of breast cancer ( Table 1) . The article was prepared in agreement with the reporting recommendations for tumor marker reporting studies [15] .
Gene-expression profiling
The Affymetrix (Santa Clara, CA) HG-U133A array and GeneChip System TM was used to quantify the relative transcript abundance in the breast cancer tissues as previously described [14] . To analyze Ep-CAM expression 201839_s_at was used. Raw .cel file, MAS 5.0 .txt file and patient data have already been deposited with accession number GSE11121 under http://www.ncbi.nlm.nih.gov/geo.
Previously published microarray datasets
Two breast cancer Affymetrix HG-U133A microarray datasets including patient outcome information were downloaded from the NCBI GEO data repository (http:// www.ncbi.nlm.nih.gov/geo/). The first data set (GSE2034) represents 180-lymph-node-negative relapse free patients and 106-lymph-node-negative patients that developed a distant metastasis. None of these patients had received systemic neoadjuvant or adjuvant therapy (Rotterdam cohort (n = 286), [11] ). The .txt file data were recalculated to a TGT of 500. The second data set (from GSE6532 and GSE7390) consists of 302 samples from breast cancer patients that remained untreated in the adjuvant setting after surgery (Transbig cohort, [12, 13] ). Raw .cel file data were processed by MAS 5.0 using a TGT of 500.
Analysis of microarray data
For our Mainz dataset, selection of ''informative'' genes was made using (a) quality control criteria as provided by the Affymetrix software, (b) the absolute median signal intensity, and (c) the coefficient of variation of a gene within our dataset as previously described [14] . Genes passing the quality control filter of having a ''present'' call in at least 10 samples, median signal intensity above 75 and a coefficient of variation above 60% within our dataset were considered to be informative and used for subsequent analysis. For unsupervised analysis, we performed average linkage hierarchical clustering on all informative genes and samples using Pearson correlation as implemented in GeneSpring 7.0 software (Agilent Technologies, USA). Gene groups were defined after manual selection of nodes of the gene dendrogram as suggested by the occurrence of cluster regions within the heatmap. Gene Ontology (GO) annotations of genes contained within a cluster were tested by Fisher's exact test for overrepresentation of specific GO terms using the Expressionist software (GeneData AG, Basel, Switzerland). A metagene was calculated as representative of all genes contained within one gene cluster based on the median of the normalized expression values within the respective cluster; per-gene normalization within the validation cohorts was done using median values obtained in the discovery cohort as previously described [14] . For further analysis, we used the previously described proliferation metagene [14] .
Statistical analysis
Survival rates were calculated according to the KaplanMeier method. MFS was computed from the date of diagnosis to the date of distant metastasis or death from cancer if there was no earlier recurrence for the patients with gene-expression profiling available to allow for comparison with the pooled validation dataset. Survival time was compared with the Log-rank test. Multivariate Cox survival analyses were performed with inclusion [16] . Dichotomization was performed as described by Schmidt et al. [10] . Differences in Ep-CAM RNA expression between patients with different immunohistochemically determined Ep-CAM status or Ep-CAM scores, histological grade, and pT stage were analyzed using the MannWhitney and the Kruskal-Wallis tests. Correlation between the proliferation metagene and Ep-CAM RNA expression was analyzed by the Spearman test. We used the gene list from Smid et al. [17] to cluster our patients (Mainz cohort) into intrinsic subtypes. Differences of Ep-CAM RNA levels between the individual intrinsic subtypes were analyzed by the Mann-Whitney test. All P-values are two-sided. As no correction for multiple testing was performed, they are descriptive measures. All analyses were performed using SPSS17.0.
Results

Correlation of Ep-CAM RNA and protein expression
The aim of this study was to compare the prognostic value of Ep-CAM RNA and immunohistochemically determined Ep-CAM protein expression in node-negative breast cancer. Therefore, we first analyzed whether both parameters correlate with each other. Ep-CAM RNA and protein expression were determined in tumor tissue of 194 patients with node-negative breast cancer (Mainz cohort). Ep-CAM RNA expression showed a unimodal distribution with a mean value and standard deviation of 11.6 and 0.84 (relative units, Fig. 1a ). Immunohistochemically determined Ep-CAM was evaluated using the Ep-CAM score and the Ep-CAM status (Fig. 1b) . Ep-CAM status also showed a statistically significant association with Ep-CAM RNA expression ( Fig. 1c , P = 0.001, Mann-Whitney test). Also the Ep-CAM score was significantly associated with levels of Ep-CAM RNA ( Fig. 1d , P = 0.001, Kruskal-Wallistest). However, the association between Ep-CAM RNA and protein was not linear. Ep-CAM scores of 0 showed the lowest and Ep-CAM scores of 12 the highest RNA expression levels, whereas Ep-CAM scores of 1-9 were intermediate (Fig. 1d) . In addition, the difference in RNA expression levels between immunohistochemically positive and negative tumors was relatively small (Fig. 1c, d) expression appeared to be prognostic, independent from the established clinical factors (Table 2B , P = 0.017, HR = 2.0). A similar result was obtained for analysis of MFS, where Ep-CAM RNA was significant in the univariate (P = 0.003, HR = 2.5) and in the multivariate (P = 0.049, HR = 1.9) Cox analysis ( Table 2) . Also for analysis of OS Ep-CAM RNA expression was significant in the univariate (P = 0.002, HR = 3.1) and in the multivariate (P = 0.042, HR = 2.3) Cox analysis (Supplemental Table 1 ). The influence of Ep-CAM RNA expression on DFS (Fig. 2a) , MFS (Fig. 2b) , and OS ( Fig. 2c ) was visualized by KaplanMeier analysis. Similar results were obtained if Ep-CAM RNA expression was dichotomized at the median (Fig. 2) or at the 75% percentile (Supplemental Fig. 1 ). Compared to Ep-CAM RNA the association of the immunohistochemically determined Ep-CAM status with prognosis was weaker. Trends toward shorter survival times were observed by Kaplan-Meier analysis for DFS, MFS, and OS time in Ep-CAM status positive patients (Supplemental Fig. 2 ). However, this amounted to statistical significance only for OS time (P = 0.031, Supplemental Fig. 2C ). In contrast to Ep-CAM RNA levels, the immunological Ep-CAM status was not significantly associated with DFS (Supplemental Table 2 ), metastasis-free interval (Supplemental Table 3 ), and OS (Supplemental Table 4 ) in the multivariate Cox regression analysis. In conclusion, high Ep-CAM RNA levels are associated with poor prognosis in the Mainz cohort and seem to perform even better compared to the immunohistochemically determined Ep-CAM status.
Validation in two independent cohorts
In a next step, we studied whether the prognostic relevance of Ep-CAM RNA observed in the Mainz cohort can be validated in two independent cohorts. For this purpose the availability of the established clinical parameters (age, pTstage, grading, hormone, and Her-2 receptor status) is important to allow multivariate Cox analysis similar as shown for the Mainz cohort in Table 2 . For the published Transbig cohort data on age, pTstage, and grading are available. However, the Her-2 status determined by immunostaining and FISH as well as the estrogen and progesterone receptor status assessed by an immunoreactive score (as available for the patients from Mainz) are not available for the Transbig cohort. In order to achieve a multivariate analysis, we reverted to the published gene array data. Estrogen receptor, Her-2, and progesterone receptor RNA expression showed a bimodal distribution in tumor tissue (Supplemental Fig. 3 ). The cutpoints differentiating between high and low expression were identified in the combined cohort of patients from Mainz, Rotterdam and the Transbig group (Supplemental Fig. 3 ). This seems to be Fig. 4A-C) . Therefore, the cutpoints of 10.0 (estrogen receptor), 12.6 (Her-2), and 4.9 (progesterone receptor) could be used for all cohorts. In the Mainz cohort results of positive HER2, ER, and PR status derived from the RNA expression data and from the immunostaining results showed an excellent correlation in the Chi-square test with P \ 0.001, respectively (Supplemental Table 5 ). Using these cutpoints, patients in the Transbig cohort were dichotomized into Her-2 as well as hormone receptor high versus low (patients characteristics: Supplemental Table 6 ). Both, univariate (P = 0.006) and multivariate (P = 0.035) analysis of the Transbig cohort demonstrated the prognostic relevance of Ep-CAM RNA for MFS (Table 3) . Since this type of analysis differs from that shown for the Mainz cohort in Table 2 concerning the classification of Her-2 and hormone receptors, we applied the technique of gene array based classification also for the Mainz cohort to obtain comparable conditions to the Transbig cohort (Supplemental Table 8 ). Dichotomizing Her-2 and the hormone receptors by gene array data in the Mainz cohort resulted in a similarly significant association of Ep-CAM RNA with MFS (Supplemental Table 8 ) as for the conventional Her-2 and hormone receptor status based on immunostaining and FISH (Table 2 ). In conclusion, similar to the results obtained from the Mainz patients, Ep-CAM RNA is also an independent prognostic factor in the Transbig cohort.
In a next step, the cohorts were combined and the influence of Ep-CAM RNA expression was visualized by Kaplan-Meier analysis. In the Transbig cohort alone (n = 302), Ep-CAM showed a significant association with MFS (P = 0.042; Fig. 3a) , whereas in the Rotterdam cohort only a trend was obtained (P = 0.089; Fig. 3b the median. The respective data after dichotomization at the 75% percentile resulted in similar associations between Ep-CAM RNA and prognosis (Supplemental Fig. 1 ). The numbers below the diagrams represent patients at risk at the time point indicated on the x-axis the case number increased to n = 588 a P-value of P = 0.002 was obtained (Fig. 3c) . Not all clinical parameters of the Rotterdam cohort are publicly available. Therefore, this group of patients could not be analyzed by multivariate Cox regression. Next, we included also the Mainz patients into a large combined cohort with 782 patients, resulting in a P-value of P \ 0.001 (Fig. 3d) . Therefore, the prognostic relevance of Ep-CAM initially analyzed in the Mainz cohort (Fig. 2, Table 2 ) could be confirmed in two further cohorts of node-negative breast cancer.
Ep-CAM correlates with the proliferation metagene and is associated with the intrinsic subtype Recently, progress has been achieved in predicting breast cancer prognosis by gene expression metagenes [14, 18] . Therefore, we analyzed, whether Ep-CAM correlates with these metagenes. A relatively good correlation was observed with the proliferation metagene (P \ 0.001, R = 0.425, Supplemental Fig. 5 ). Therefore, one might expect that the metagene that comprises the information of a multitude of genes performs superior over an individual gene in multivariate analysis. Surprisingly, this was not the case. When all three cohorts were combined (n = 782) Ep-CAM was significant in multivariate analysis (P = 0.004), in contrast to the proliferation metagene (P = 0.114) (Table 4A) . Also if the individual subcohorts were analyzed, including the clinical factors, Ep-CAM and not the proliferation metagene was significant in multivariate analysis (Table 4B) . Recently, Sieuwerts et al. [19] have analyzed Ep-CAM expression in breast cancer cell lines with different intrinsic subtype characteristics. They reported that cell lines of the ''normal-like'' subgroup express particularly low levels of Ep-CAM. Therefore, we clustered our patients into intrinsic subtypes and compared levels of Ep-CAM RNA (Supplemental Fig. 6 ). We confirmed the observation of Sieuwerts et al. [19] . Expression of Ep-CAM was significantly lower in normal-like carcinomas compared to basal-like, ERBB2-like or luminal B subtypes (P \ 0.001; Supplemental Fig. 6 ).
Gene array data presented in this study were log2 transformed and dichotomized cohortwise at the 75% percentile. We used this type of transformation, because in previous studies of adverse prognostic factors we have observed that particularly the 25% of patients with highest expression show an increased hazard ratio [16, 20] . However, the prognostic influence of Ep-CAM RNA does not depend on a particular mode of data transformation, since also untransformed Ep-CAM RNA expression data and log2 transformed data dichotomized at the median instead of the 75% percentile also resulted in significant associations.
Discussion
Even though Ep-CAM was initially described as a cellular adhesion molecule [1] , recent insights revealed a more complex role for Ep-CAM, not merely limited to cell adhesion but also facilitating processes such as cell signaling, cell migration, proliferation, and differentiation [21] . Silencing Ep-CAM gene expression with Ep-CAM short interfering RNA resulted in a substantial decrease in the rate of cell proliferation, migration, and invasion in breast cancer cell lines [22] , which supports the notion that the role of Ep-CAM in carcinomas is pleiotropic [21] . Ep-CAM overexpression has been reported to be associated with adverse prognosis in node-positive [8] as well as node-negative breast cancer [10] , whereby Ep-CAM has been evaluated by immunostaining. Compared with immunostaining, RNA analysis has the advantage of less inter-and intra-observer variability. Furthermore, the results can be validated in previously published cohorts of patients characterized by gene array analyses. To validate Ep-CAM RNA expression as a possible prognostic factor in breast cancer, we first studied the correlation between Ep-CAM RNA and protein expression. Affymetrix HG-U133A and immunostaining data were available for 194 node-negative breast carcinomas from the Mainz cohort. Ep-CAM status positive tumors had significantly higher levels of Ep-CAM RNA expression. However, there was no linear relationship between immunostaining and RNA expression data. This became obvious when we compared the Ep-CAM score, a product of the fraction of positive cells and their staining intensity, with RNA expression levels (Fig. 1) . Although the highest and lowest scores were associated with high and low RNA expression, no correlation was seen for the intermediate scores.
Therefore, we next compared the prognostic relevance of RNA and protein in the Mainz cohort. Interestingly, Ep-CAM expression was associated with DFS and also with metastasis-free interval, independently from the clinically established factors age, pTstage, grading, hormone receptor, and HER-2 status, whereas Ep-CAM immunostaining data showed only a trend. The latter result does not contradict previously published studies where Ep-CAM was reported to be associated with prognosis, because the discrepancy can be explained by differences in case numbers. Both, RNA and immunostaining data were available in only 194 patients (present study), whereas the previously published associations between Ep-CAM immunostaining and prognosis were found in cohorts of 1,705 [8] and 402 [10] patients. In a next step, we validated the prognostic relevance of Ep-CAM RNA expression in independent cohorts. Very similar results as for the Mainz cohort were found in the previously published Transbig cohort [12, 13] of 302 node-negative breast cancer patients, where Ep-CAM RNA was also associated with metastasis-free interval independent from age, pTstage, grading, hormone receptor, and HER-2 status. Unfortunately, a third cohort, the Rotterdam patients of node-negative breast cancer [11] could not be evaluated by multivariate analysis, because the clinical data have not been completely published. However, in Kaplan-Meier analysis the single cohorts as well as combined cohorts were associated with survival time. The relevance of Ep-CAM is also illustrated by the decreasing P-value of the log-rank-test with increasing case numbers with P = 0.042 for the Transbig cohort only (n = 302), P = 0.002 for the combined Transbig plus Rotterdam cohorts (n = 588) and P \ 0.001 for all three cohorts with n = 782 patients. Recently, a genome wide overview of the natural history of node-negative breast cancer has been published, in which three major biological axes, (i) the transition from slow to fast proliferation, (ii) immune cell infiltration, and (iii) steroid hormone receptor expression allow deeper understanding of biological processes relevant for breast cancer progression [14, 18] . Transition from slow to fast proliferation, leads to the most dramatic aggravation of prognosis. When we studied the relationship between Ep-CAM and the above mentioned ''coordinates in the universe of nodenegative breast cancer'' [18] , we observed a strong correlation between Ep-CAM RNA expression and the proliferation metagene. A metagene roughly represents a distinct biological motif as indicated by the genes constituting the respective cluster. Proliferation was the most significant independent prognostic motif in earlier studies [14, [23] [24] [25] [26] . Since we initially expected that the prognostic information of Ep-CAM expression may be already covered by the powerful proliferation metagene, we included both, Ep-CAM and the proliferation metagene, into the multivariate Cox model. Bearing the well-documented strong correlation of proliferation and outcome in mind, it is astonishing that a single gene, Ep-CAM, is superior to the proliferation metagene in multivariate analysis (Table 3) . On the other hand, considering the numerous potential functions of Ep-CAM aside from proliferation like cell adhesion [1] , cell migration [22] , cell cycle regulation [27] , apoptosis resistance [28] , tumor immune evasion [29] , and metastasis [30] , it is conceivable that Ep-CAM indeed possesses a significant association with outcome of breast cancer patients independent of proliferation. In conclusion, our large-scale validation of the prognostic significance of Ep-CAM RNA expression for the natural history of node-negative breast cancer makes it a valuable prognostic factor independent from established clinical factors and from the proliferation metagene, which might serve as a suitable objective for targeted therapies.
